Hikma Pharmaceuticals USA Inc. has announced the approval of its Abbreviated New Drug Application (ANDA) for leucovorin calcium oral, a therapeutic agent generically known for its pivotal role in methotrexate rescue therapy and other oncological applications. This regulatory clearance reinforces Hikma’s broad portfolio of oral generics and is expected to bolster its market position by expanding the supply chain for this critical medication through the expiration of the branded patent in 1993.